|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
1994-5-12
|
|
pubmed:abstractText |
To determine whether granulocyte colony-stimulating factor (G-CSF) administered before, during, and after fludarabine plus cytarabine (ara-C; FA) chemotherapy affected complete response (CR) rate, infection rate, blood count recovery, or survival in patients with newly diagnosed acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS).
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
12
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
N
|
|
pubmed:pagination |
671-8
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:7512125-Aged,
pubmed-meshheading:7512125-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:7512125-Bone Marrow Diseases,
pubmed-meshheading:7512125-Cytarabine,
pubmed-meshheading:7512125-Drug Administration Schedule,
pubmed-meshheading:7512125-Female,
pubmed-meshheading:7512125-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:7512125-Humans,
pubmed-meshheading:7512125-Incidence,
pubmed-meshheading:7512125-Infection,
pubmed-meshheading:7512125-Leukemia, Myeloid, Acute,
pubmed-meshheading:7512125-Male,
pubmed-meshheading:7512125-Middle Aged,
pubmed-meshheading:7512125-Myelodysplastic Syndromes,
pubmed-meshheading:7512125-Neutrophils,
pubmed-meshheading:7512125-Regression Analysis,
pubmed-meshheading:7512125-Remission Induction,
pubmed-meshheading:7512125-Survival Analysis,
pubmed-meshheading:7512125-Treatment Outcome,
pubmed-meshheading:7512125-Vidarabine
|
|
pubmed:year |
1994
|
|
pubmed:articleTitle |
Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor.
|
|
pubmed:affiliation |
Department of Hematology, University of Texas M.D. Anderson Cancer Center, Houston 77030.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Research Support, U.S. Gov't, P.H.S.
|
